Erschienen in:
01.05.2019 | Original Article
Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice
verfasst von:
Giovanni Caocci, Olga Mulas, Elisabetta Abruzzese, Alessandra Iurlo, Mario Annunziata, Ester Maria Orlandi, Sara Galimberti, Gianni Binotto, Nicola Sgherza, Luigia Luciano, Bruno Martino, Antonella Russo Rossi, Massimiliano Bonifacio, Claudio Fozza, Malgorzata Monika Trawinska, Daniele Cattaneo, Chiara Elena, Claudia Baratè, Fiorenza De Gregorio, Matteo Molica, Giorgio La Nasa, Robin Foà, Massimo Breccia
Erschienen in:
Annals of Hematology
|
Ausgabe 8/2019
Einloggen, um Zugang zu erhalten
Abstract
There is little information about cardiovascular adverse event (CV-AE) incidence in chronic myeloid leukemia (CML) patients treated with bosutinib in the real-life practice. We identified 54 consecutive CML patients treated with bosutinib, stratified according to the Systematic Coronary Risk Evaluation (SCORE) assessment, based on sex, age, smoking habits, systolic blood pressure, and total cholesterol levels. The 40-month cumulative incidence of CV-AEs was 25.2 ± 8.1%. Patients with the SCORE of high–very high showed a significantly higher incidence of CV-AEs (55 ± 12.9% vs 9 ± 9.5%; p = 0.002). Overall, 9 CV-AEs were reported, with 2 deaths attributed to CV-AE. In conclusion, the SCORE assessment before starting treatment is helpful in identifying CV-AE high-risk patients during bosutinib treatment.